Evolent Health, Inc. (EVH)

NYSE: EVH · Real-Time Price · USD
3.670
+0.590 (19.16%)
Aug 6, 2026, 1:46 PM EDT - Market open
Market Cap412.81M -64.0%
Revenue (ttm)2.10B -4.5%
Net Income-511.06M
EPS-4.54
Shares Out 112.48M
PE Ration/a
Forward PE16.00
Dividendn/a
Ex-Dividend Daten/a
Volume4,275,727
Open4.080
Previous Close3.080
Day's Range3.605 - 4.150
52-Week Range2.095 - 10.080
Beta0.78
AnalystsBuy
Price Target5.83 (+58.86%)
Earnings DateAug 6, 2026

About EVH

Evolent Health, Inc., through its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company offers integrated value-based care platform for health plan administration and management. It also provides administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, an... [Read more]

Sector Healthcare
IPO Date Jun 5, 2015
Employees 4,200
Stock Exchange NYSE
Ticker Symbol EVH
Full Company Profile

Financial Performance

In 2025, Evolent Health's revenue was $1.88 billion, a decrease of -26.56% compared to the previous year's $2.55 billion. Losses were -$579.40 million, 520.0% more than in 2024.

Financial Statements

Analyst Summary

According to 14 analysts, the average rating for EVH stock is "Buy." The 12-month stock price target is $5.83, which is an increase of 58.86% from the latest price.

Price Target
$5.83
(58.86% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Evolent Health Earnings Call Transcript: Q2 2026

Q2 2026 saw 31% revenue and 27% adjusted EBITDA growth, driven by new Performance Suite launches and strong client renewals. Full-year guidance was raised, with 2027 revenue growth expected above 25% despite Medicaid headwinds. AI initiatives and new contracts support long-term margin and growth targets.

5 hours ago - Transcripts

Evolent Health Earnings release: Q2 2026

Evolent Health released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.

5 hours ago - Filings

Evolent Health Slides: Q2 2026

Evolent Health has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.

5 hours ago - Filings

Evolent Health Quarterly report: Q2 2026

Evolent Health has published its Q2 2026 quarterly earnings report on August 6, 2026.

5 hours ago - Filings

Evolent Health reports Q2 adjusted EPS 2c, consensus (2c)

Reports Q2 revenue $652.52M, consensus $599.79M. CEO Seth Blackley stated, “We believe our results for the second quarter of 2026, our updated 2026 guidance and our 2027 outlook all demonstrate…

5 hours ago - TheFly

Evolent Health raises 2026 revenue view to $2.6B-$2.7B from $2.4B-$2.6B

2026 revenue consensus $2.5B. Tightens adjusted EBITDA guidance to $120M-$135M. Expects to deploy $25M-$30M in cash for capitalized software development during 2026.

5 hours ago - TheFly

Evolent Announces Second Quarter 2026 Results

WASHINGTON, Aug. 6, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through ...

6 hours ago - PRNewsWire

Evolent Health price target lowered to $5 from $8 at TD Cowen

TD Cowen analyst Charles Rhyee lowered the firm’s price target on Evolent Health (EVH) to $5 from $8 and keeps a Buy rating on the shares ahead of the Q2…

9 days ago - TheFly

Citi downgrades Evolent Health to Neutral on valuation after rally

Citi downgraded Evolent Health (EVH) to Neutral from Buy with a price target of $6.75, up from $5.50. The firm sees a less favorable risk/reward following the stock’s recent rally.

14 days ago - TheFly

Evolent Health downgraded to Sell from Buy at Citi

Citi analyst Daniel Grosslight downgraded Evolent Health (EVH) to Sell from Buy with a $6.75 price target

14 days ago - TheFly

Evolent Health price target raised to $7 from $6 at Canaccord

Canaccord raised the firm’s price target on Evolent Health (EVH) to $7 from $6 and keeps a Buy rating on the shares. The firm updated its model heading into the…

16 days ago - TheFly

Forget Nvidia. These 5 S&P 500 stocks are quietly going all in on AI.

The “Mag Seven” has become the “Bag Seven.” Sharp tech investors are looking elsewhere.

Other symbols: CRMNOWPGYV
17 days ago - Market Watch

Evolent To Release Second Quarter 2026 Financial Results on Thursday, August 6, 2026

WASHINGTON, July 8, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its...

4 weeks ago - PRNewsWire

Evolent Health downgraded to Hold from Buy at Truist

Truist downgraded Evolent Health (EVH) to Hold from Buy with an unchanged price target of $7. The company’s 2027 consensus EBITDA estimates do not fully reflect the headwind from Medicaid…

5 weeks ago - TheFly

Evolent Health price target raised to $5.50 from $4 at Citi

Citi raised the firm’s price target on Evolent Health (EVH) to $5.50 from $4 and keeps a Buy rating on the shares.

2 months ago - TheFly

Evolent Health price target raised to $6 from $5 at Canaccord

Canaccord raised the firm’s price target on Evolent Health (EVH) to $6 from $5 and keeps a Buy rating on the shares. The firm updated its model following mixed Q1…

3 months ago - TheFly

Evolent Health reports Q1 adjusted EPS (2c), consensus (5c)

Reports Q1 revenue $496.25M, consensus $534.04M. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, “I am happy with the strong start to the year. We are on track…

3 months ago - TheFly

Evolent Health Earnings Call Transcript: Q1 2026

Q1 2026 results showed 9% sequential revenue growth and improved MER, driven by new launches and strong demand for oncology solutions. Guidance for 2026 was reiterated, with continued investment in AI and automation and two major new contracts expected to boost future revenue.

3 months ago - Transcripts

Evolent Health Earnings release: Q1 2026

Evolent Health released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.

3 months ago - Filings

Evolent Health Slides: Q1 2026

Evolent Health has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.

3 months ago - Filings

Evolent Health Quarterly report: Q1 2026

Evolent Health has published its Q1 2026 quarterly earnings report on May 7, 2026.

3 months ago - Filings

Evolent Announces First Quarter 2026 Results

WASHINGTON, May 7, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through p...

3 months ago - PRNewsWire

Evolent Health Proxy statement: Proxy filing

Evolent Health filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.

3 months ago - Filings

Evolent Health Proxy statement: Proxy filing

Evolent Health filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.

3 months ago - Filings

Evolent To Release First Quarter 2026 Financial Results on Thursday, May 7, 2026

WASHINGTON, April 7, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release it...

4 months ago - PRNewsWire